Shares

10 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2022

Aug 15, 2022

SELL
$0.47 - $1.29 $63 - $174
-135 Reduced 0.12%
115,414 $63,000
Q1 2022

May 16, 2022

BUY
$0.96 - $1.78 $4,538 - $8,415
4,728 Added 4.27%
115,549 $128,000
Q4 2021

Feb 14, 2022

BUY
$1.56 - $2.99 $32,916 - $63,089
21,100 Added 23.52%
110,821 $191,000
Q3 2021

Nov 15, 2021

BUY
$2.73 - $4.13 $17,472 - $26,432
6,400 Added 7.68%
89,721 $275,000
Q2 2021

Aug 16, 2021

SELL
$2.18 - $4.29 $690,678 - $1.36 Million
-316,825 Reduced 79.18%
83,321 $325,000
Q1 2021

May 17, 2021

SELL
$2.69 - $5.12 $73,046 - $139,033
-27,155 Reduced 6.36%
400,146 $1.12 Million
Q4 2020

Feb 16, 2021

SELL
$2.25 - $7.12 $26,484 - $83,809
-11,771 Reduced 2.68%
427,301 $1.31 Million
Q3 2020

Nov 10, 2020

SELL
$3.46 - $8.39 $211,087 - $511,857
-61,008 Reduced 12.2%
439,072 $2.67 Million
Q2 2020

Aug 14, 2020

SELL
$2.37 - $7.14 $88,249 - $265,865
-37,236 Reduced 6.93%
500,080 $2.96 Million
Q1 2020

May 11, 2020

BUY
$2.46 - $5.84 $1.32 Million - $3.14 Million
537,316 New
537,316 $1.42 Million

Others Institutions Holding CYCN

# of Institutions
1
Shares Held
293K
Call Options Held
0
Put Options Held
0

About Cyclerion Therapeutics, Inc.


  • Ticker CYCN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 43,479,800
  • Market Cap $153M
  • Description
  • Cyclerion Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovering, development, and commercialization of medicines for serious central nervous system (CNS) diseases. Its lead product candidate is CY6463, a CNS-penetrant, soluble guanylate cyclase (sGC) stimulator that is in Phase IIa trials for the treatment of...
More about CYCN
Track This Portfolio

Track State Street Corp Portfolio

Follow State Street Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of State Street Corp, based on Form 13F filings with the SEC.

News

Stay updated on State Street Corp with notifications on news.